Contents

Issue 154 • May 2025

In association with

Cover Story

The GLP-1 drug shortage is over. What’s next for the compounders?

Interview

Saving shelved ultra-rare therapies through unorthodox funding

Analyst Comment

Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts?

In Depth

The GLP-1 drug shortage is over. What’s next for the compounders?

Big pharma faces headwinds in China as vaccine sales decline

How can pharma manage rising trial costs?

Can AI replace medical writers? Experts say not immediately

Saving shelved ultra-rare therapies through unorthodox funding

Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts?

Weight loss implants to increase compliance and cut admin burden for patients

Briefing

News in Numbers

Latest News

Latest Deals

04/29/2025 12:21:00
  • Home | The GLP-1 drug shortage is over. What’s next for the compounders?
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • MilliporeSigma
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • ZETA
  • In Depth
  • The GLP-1 drug shortage is over. What’s next for the compounders?
  • Big pharma faces headwinds in China as vaccine sales decline
  • How can pharma manage rising trial costs?
  • Can AI replace medical writers? Experts say not immediately
  • Saving shelved ultra-rare therapies through unorthodox funding
  • Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts?
  • Weight loss implants to increase compliance and cut admin burden for patients
  • Greens Company Insight
  • Listings
  • Events
  • Excellence Awards
  • Buyer's Guides
  • Next issue
04/29/2025 00:00:00